28,906 resources
By Version
By Authority
By Realm
Start Prev Rows 2000 - 2200 Next
Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Realm | Auth | Source(s) |
---|---|---|---|---|---|---|---|---|---|---|
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.40 | Portable Medical Order Document Types | active | 2025-04 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.41 | Advance Healthcare Directive Document Types Grouper | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.8 | Treatment Intervention Preferences at End of Life LOINC | active | 2025-04 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.1 | Rituximab Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.100 | Pathological M Stage M1c | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.101 | Pathological N Stage N3 | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.102 | N Stage pN1a | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.103 | N Stage pN1b | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.105 | Pathological N Stage pN1mi | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.106 | Pathological N Stage N2b | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.107 | Pathological N Stage N2a | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.108 | Pathological N Stage N2 | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.109 | Pathological N Stage N1b | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.110 | Pathological N Stage N1a | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.112 | Pathological N Stage N0 | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.114 | Pathological T Stage T4d | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.115 | Pathological T Stage T4c | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.116 | Pathological T Stage T4b | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.117 | Pathological T Stage T4a | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.118 | Pathological T Stage T4 | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.120 | N Stage N2C | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.121 | T Stage T3c | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.122 | T Stage T3b | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.123 | T Stage T3a | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.124 | Pathological T Stage T3 | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.125 | T Stage T2c | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.126 | T Stage T2b | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.127 | T Stage T2a | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.128 | Pathological T Stage T2 | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.129 | Pathological T Stage T1c | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.132 | Pathological T Stage T1b | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.135 | Pathological T Stage T1a | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.136 | Pathological T Stage T1 | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.137 | Pathological T Stage T1mic | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.139 | Pathological T Stage T0 | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.142 | Cancer Stage III | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.143 | Cancer Stage IIIA | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.144 | Cancer Stage IIIB | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.145 | Cancer Stage IIIC | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.146 | Cancer Stage IV | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.147 | Cancer Stage IVA | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.148 | Cancer Stage IVB | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.149 | Cancer Stage IVC | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.151 | Cisplatin Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.153 | Vinorelbine Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.154 | Gemcitabine Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.155 | Docetaxel | active | 2024-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.156 | Pemetrexed Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.158 | Vinblastine Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.160 | ECOG Performance Status | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.161 | ECOG Performance Status | active | 2020-10 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.162 | ECOG Performance Status | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.164 | Karnofsky Performance Status | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.165 | Carboplatin Injectable | active | 2020-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.166 | Paclitaxel | active | 2024-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.168 | Doxorubicin Injectable | active | 2022-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.169 | Irinotecan Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.179 | Bevacizumab Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.181 | Methotrexate | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.184 | Breast Cancer | active | 2022-06 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.185 | Breast Cancer | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.191 | Cancer Stage II | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.192 | Cancer Stage IIA | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.193 | Cancer Stage IIB | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.194 | Pertuzumab Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.196 | Ixabepilone Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.197 | Goserelin | active | 2024-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.200 | Epirubicin Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.202 | Ramucirumab Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.204 | Letrozole | active | 2024-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.206 | Exemestane | active | 2024-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.209 | Fluorouracil | active | 2024-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.210 | Capecitabine Oral | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.222 | Aprepitant Oral | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.223 | Fosaprepitant Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.255 | Colorectal Cancer | active | 2021-12 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.256 | Colorectal Cancer | active | 2021-12 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.257 | Colorectal Cancer Chemotherapy | active | 2023-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.280 | Cancer Stage IA | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.281 | Cancer Stage IB | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.286 | Cancer Stage IIC | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.291 | Positive Result | active | 2024-12 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.292 | Negative Result | active | 2015-12 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.300 | Pathological N Stage N1C | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.332 | Daunorubicin Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.336 | Palonosetron Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.341 | External Beam Radiotherapy | active | 2024-04 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.349 | Metastatic Cancer | active | 2023-12 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.439 | T Category | active | 2018-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.440 | N Category | active | 2018-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.441 | M Category | active | 2018-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.442 | TNM Stage Group | active | 2018-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.449 | Opioids | active | 2024-03 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.492 | Pharmacological interventions for depression | active | 2024-05 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.535 | Ovarian Cancer | active | 2023-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.536 | Ovarian Cancer | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.537 | Fallopian Tube Cancer | active | 2022-06 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.539 | Fallopian Tube Cancer | active | 2022-06 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.541 | Peritoneal Cancer | active | 2022-06 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.542 | Peritoneal Cancer | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.547 | Cancer Stage 1C | active | 2024-12 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.555 | Gender Female | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.556 | Gender Male | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.557 | Pathological N Stage N3a | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.558 | Pathological N Stage N3b | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.560 | Rolapitant Oral | active | 2024-07 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.599 | Obinutuzumab Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.600 | Ofatumumab Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.602 | Neurokinin 1 Receptor Antagonist | active | 2024-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.604 | Serotonin Receptor Antagonist | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.61 | Cetuximab Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.63 | Panitumumab Injectable | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.81 | Palonosetron Oral | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.88 | Lung Cancer | active | 2015-08 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.89 | Lung Cancer | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.95 | M Stage M0 | active | 2024-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.97 | Pathological M Stage M1 | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.98 | Pathological M Stage M1a | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.99 | Pathological M Stage M1b | active | 2024-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1125.7 | PROMIS Depression Assessment | active | 2023-05 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.11 | Sleep Apnea | active | 2018-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.13 | Septic Shock due to C. Diff | active | 2019-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.15 | Body Temperature | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.16 | Diarrhea Potentially due to CDI | active | 2019-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.17 | Abdominal Distension | active | 2019-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.18 | Vomiting potentially due to CDI | active | 2019-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.19 | Ileus due to infection | active | 2019-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.20 | Clostridium difficile infection | active | 2019-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.3 | Radiation Therapy Indicators from CPT | active | 2017-03 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.4 | Diagnostic Radiology Surrounding Face and Sinus | active | 2017-03 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.5 | Ear Surgery Affecting the Tympanic Membrane | active | 2017-03 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.6 | Allergic Rhinitis Immunotherapy | active | 2017-06 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.8 | Radiology to Head and Sinus | active | 2017-06 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1130.9 | Immunotherapy For Allergic Rhinitis | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1136.63 | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2024-07 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.1 | C2S Alcohol Use Disorders | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.11 | C2S Amphetamine Use Disorders | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.12 | C2S Cannabis Use Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.13 | C2S Cannabis Use Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.14 | C2S Cannabis Use Disorders | active | 2016-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.15 | C2S Cannabis Use DIsorders | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.16 | C2S Cocaine Use Disorder | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.17 | C2S Cocaine Use Disorder | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.18 | C2S Cocaine Use Disorder | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.19 | C2S Hallucinogens | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.2 | C2S Alcohol Use Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.20 | C2S Hallucinogens | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.21 | C2S Hallucinogens | active | 2016-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.22 | C2S Hallucinogens | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.23 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | us | hl7 | cms | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.24 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.25 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.26 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.27 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.28 | C2S Inhalants | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.29 | C2S Inhalants | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.3 | C2S Alcohol Use Disorders | active | 2016-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.30 | C2S Inhalants | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.32 | C2S Mental Health Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.33 | C2S Mental Health Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.34 | C2S Mental Health Disorders | active | 2016-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.35 | C2S Mental Health Disorders | active | 2016-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.36 | C2S Mental Health Disorders | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.38 | C2S Opioids | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.39 | C2S Opioids | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.4 | C2S Alcohol Use Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.40 | C2S Opioids | active | 2016-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.42 | C2S Opioids | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.43 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.44 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.45 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.46 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.47 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.48 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.49 | C2S Sexuality and reproductive health information sensitivity | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.5 | C2S Alcohol Use Disorders | active | 2016-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.51 | C2S Tobacco Use Disorders | active | 2016-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.52 | C2S Tobacco Use Disorders | active | 2016-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.53 | C2S Tobacco Use Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.54 | C2S Tobacco Use Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.55 | C2S Substance Use Information Sensitivity | active | 2016-09 | us | hl7 | cms | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.56 | C2S Substance Use Information Sensitivity | active | 2016-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.58 | C2S Sensitive Categories | active | 2016-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.59 | C2S Opioids | active | 2016-09 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.6 | C2S Amphetamine Use Disorders | active | 2016-09 | us | hl7 | cms | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.60 | C2S HIV/AIDS information Sensitivity | active | 2016-09 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.65 | Test C2S Alcohol Use Disorders | active | 2019-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.67 | Test C2S HIV/AIDS Information Sensitivity | active | 2019-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.7 | C2S Amphetamine Use Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.8 | C2S Amphetamine Use Disorders | active | 2016-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1142.9 | C2S Amphetamine Use Disorders | active | 2016-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.10 | Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method) | active | 2024-06 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.1002 | Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method) | active | 2023-06 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.1012 | S. Typhi Infection (Disorders) (SNOMED) | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.1016 | S. Paratyphi Infection (Disorders) (SNOMED) | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.1017 | S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method) | active | 2024-06 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.1021 | Dark Urine (SNOMED) | active | 2023-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.1022 | Acute Onset [Qualifier Value] (SNOMED) | active | 2024-01 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.1024 | Acute Viral Hepatitis (SNOMED) | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.1027 | Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM) | active | 2023-06 | us | hl7 | icd |